Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers Super Bowl ad stirs up controversy with lawmakers
Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
1don MSNOpinion
The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...
Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback